Skip to main content

Cancer Immunotherapy, Vaccination

  1. Preclinical and clinical studies have demonstrated that immunotherapy has effectively delayed tumor progression, and the clinical outcomes of anti-PD-1/PD-L1 therapy were related to PD-L1 expression level in t...

    Authors: Sheng Zhao, Wenbin Pan, Huijie Jiang, Rongjun Zhang, Hao Jiang, Zonghui Liang and Hongbo Hu
    Citation: EJNMMI Research 2020 10:64
  2. Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring PD-L1 expression could help to select NSCLC ...

    Authors: Xiaodong Wu, Yan Huang, Qingping Zhao, Lei Wang, Xiao Song, Yi Li and Lei Jiang
    Citation: EJNMMI Research 2020 10:51
  3. Anti-programmed cell death 1 (PD-1) antibody is an immune checkpoint inhibitor, and anti-PD-1 therapy improves the anti-tumor functions of T cells and affects tumor microenvironment. We previously reported tha...

    Authors: Mayu Tomita, Motofumi Suzuki, Yusuke Kono, Kohei Nakajima, Takuma Matsuda, Yuji Kuge and Mikako Ogawa
    Citation: EJNMMI Research 2020 10:24